VENLO, The Netherlands and HILDEN, Germany, September 10, 2016 /PRNewswire/ --
QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) commented on a decision issued late on Friday, September 9, by the U.S. District Court for the Northern District of California, San Francisco
"While we are disappointed and disagree with the Court's decision, we believe our intellectual property position in next-generation sequencing is strong, and we are pursuing all legal means to get the current decision reviewed by the U.S. Court of Appeals for the Federal Circuit as soon as possible," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. "The disputed intellectual property claim is related to a narrow step within the overall broad GeneReader NGS workflow. In addition, QIAGEN intends to accelerate the development already underway of an upgrade to the component under dispute to resume U.S. commercialization with a full workflow of at least comparable or even better performance. The issue in this case also applies only in the United States, so customers in all other regions of the world can continue to purchase and use the GeneReader NGS System."
Click here for the full release
Contacts: Public Relations: Dr. Thomas Theuringer Senior Director Public Relations +49-2103-29-11826 Email: [email protected] http://www.twitter.com/qiagen https://www.facebook.com/QIAGEN pr.qiagen.com
Investor Relations: John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 Email: [email protected] ir.qiagen.com
SOURCE QIAGEN N.V.
Subscribe to our Free Newsletters!
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...
Bile duct cancer occurs either within the liver or the point where the bile ducts emerge from the ...
Xeroderma pigmentosum is a rare inherited condition marked by extreme sensitivity to sunlight and ...View All